Transcenta Therapeutics, a global biopharmaceutical company with capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical development and manufacturing company.

Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.

Transcenta will be eligible to receive a substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies.

The HiCB platform is designed to deliver greater process efficiency, improve process control and product consistency, and significantly reduce cost of goods compared to conventional fed-batch manufacturing process, ultimately contributing to the goal of expanded global patient access to high-quality, affordable biologics.

EirGenix will adopt Transcenta’s HiCB platform to support its biologics development programs and manufacturing operations. EirGenix plans to apply the HiCB platform to serve CDMO clients pursuing intensified and continuous manufacturing solutions.

“We are pleased to share our HiCB platform, a result of Transcenta’s leadership in highly intensified continuous bioprocessing, with partners who share our vision of transforming biologics manufacturing,” said Dr. Xueming Qian, Chairman and CEO of Transcenta. “By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics. The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best-in-class therapeutics.”

“This collaboration represents a win–win partnership that combines Transcenta’s innovation in continuous biomanufacturing and EirGenix’s proven bioprocessing and CDMO expertise,” said Dr. L.-C. Liu, Chairman and President of EirGenix. “Together, we aim to redefine how biologics are made—more efficiently, sustainably, and at lower cost—to reach more patients worldwide.”